Laura Dunn
Concepts (464)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Informed Consent | 37 | 2017 | 92 | 6.060 |
Why?
| Neoplasms | 47 | 2023 | 1322 | 5.430 |
Why?
| Decision Making | 31 | 2017 | 286 | 4.180 |
Why?
| Mental Competency | 23 | 2017 | 33 | 2.800 |
Why?
| Depression | 26 | 2022 | 596 | 2.690 |
Why?
| Breast Neoplasms | 31 | 2022 | 1249 | 2.670 |
Why?
| Biomedical Research | 14 | 2019 | 241 | 2.370 |
Why?
| Patient Participation | 7 | 2019 | 68 | 2.350 |
Why?
| Fatigue | 23 | 2023 | 128 | 2.240 |
Why?
| Clinical Trials as Topic | 19 | 2023 | 491 | 2.160 |
Why?
| Quality of Life | 28 | 2023 | 924 | 2.140 |
Why?
| Schizophrenia | 16 | 2008 | 267 | 2.110 |
Why?
| Research Subjects | 12 | 2019 | 57 | 2.090 |
Why?
| Psychiatry | 9 | 2018 | 116 | 1.990 |
Why?
| Third-Party Consent | 7 | 2013 | 13 | 1.920 |
Why?
| Middle Aged | 104 | 2021 | 13082 | 1.800 |
Why?
| Adaptation, Psychological | 9 | 2022 | 243 | 1.640 |
Why?
| Schizophrenic Psychology | 12 | 2011 | 71 | 1.630 |
Why?
| Clergy | 3 | 2017 | 24 | 1.620 |
Why?
| Caregivers | 13 | 2021 | 241 | 1.620 |
Why?
| Internship and Residency | 9 | 2011 | 501 | 1.600 |
Why?
| Female | 130 | 2023 | 28471 | 1.570 |
Why?
| Alzheimer Disease | 8 | 2021 | 369 | 1.530 |
Why?
| Humans | 174 | 2024 | 54391 | 1.490 |
Why?
| Ethics, Research | 8 | 2016 | 41 | 1.470 |
Why?
| Anxiety | 13 | 2022 | 279 | 1.440 |
Why?
| Stress, Psychological | 12 | 2021 | 270 | 1.440 |
Why?
| Antineoplastic Agents | 14 | 2020 | 1300 | 1.430 |
Why?
| Proxy | 4 | 2013 | 10 | 1.380 |
Why?
| Aged | 79 | 2020 | 10060 | 1.340 |
Why?
| Mental Disorders | 10 | 2019 | 445 | 1.330 |
Why?
| Psychotherapy | 5 | 2014 | 106 | 1.280 |
Why?
| Male | 98 | 2022 | 27347 | 1.260 |
Why?
| Adult | 67 | 2020 | 14207 | 1.260 |
Why?
| Depressive Disorder | 10 | 2023 | 368 | 1.220 |
Why?
| Cognition Disorders | 11 | 2021 | 240 | 1.200 |
Why?
| Comprehension | 7 | 2016 | 115 | 1.150 |
Why?
| Patient Preference | 2 | 2016 | 37 | 1.110 |
Why?
| Spiritual Therapies | 2 | 2017 | 6 | 1.110 |
Why?
| Patients | 4 | 2020 | 53 | 1.110 |
Why?
| Cytokines | 10 | 2017 | 677 | 1.050 |
Why?
| Palliative Care | 3 | 2017 | 188 | 1.050 |
Why?
| Psychotic Disorders | 9 | 2018 | 143 | 1.040 |
Why?
| Dementia | 3 | 2017 | 150 | 1.020 |
Why?
| Longitudinal Studies | 32 | 2021 | 742 | 1.000 |
Why?
| Education | 4 | 2011 | 46 | 0.990 |
Why?
| Personality | 2 | 2022 | 31 | 0.940 |
Why?
| Therapeutic Misconception | 4 | 2017 | 4 | 0.900 |
Why?
| Genetic Research | 2 | 2019 | 4 | 0.890 |
Why?
| Ambulatory Care | 7 | 2017 | 231 | 0.880 |
Why?
| Mastectomy | 8 | 2021 | 143 | 0.860 |
Why?
| Aged, 80 and over | 25 | 2020 | 3431 | 0.860 |
Why?
| Attitude of Health Personnel | 3 | 2011 | 390 | 0.830 |
Why?
| Psychiatric Status Rating Scales | 10 | 2017 | 346 | 0.810 |
Why?
| Polymorphism, Single Nucleotide | 14 | 2017 | 552 | 0.770 |
Why?
| Patient Rights | 2 | 2019 | 2 | 0.770 |
Why?
| Severity of Illness Index | 24 | 2019 | 1082 | 0.770 |
Why?
| Mental Health | 5 | 2016 | 245 | 0.740 |
Why?
| Radiotherapy | 3 | 2018 | 137 | 0.730 |
Why?
| Geriatric Psychiatry | 3 | 2017 | 11 | 0.730 |
Why?
| Self Concept | 1 | 2020 | 71 | 0.710 |
Why?
| Deep Brain Stimulation | 4 | 2014 | 49 | 0.710 |
Why?
| Health Services Research | 4 | 2016 | 165 | 0.660 |
Why?
| Choroid Neoplasms | 1 | 2018 | 7 | 0.640 |
Why?
| Eye Enucleation | 1 | 2018 | 13 | 0.640 |
Why?
| Anxiety Disorders | 6 | 2022 | 138 | 0.640 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 231 | 0.640 |
Why?
| Patient Selection | 7 | 2016 | 284 | 0.610 |
Why?
| Pain | 10 | 2023 | 405 | 0.600 |
Why?
| Needs Assessment | 3 | 2015 | 153 | 0.600 |
Why?
| Comorbidity | 12 | 2021 | 664 | 0.600 |
Why?
| Self Report | 13 | 2021 | 205 | 0.590 |
Why?
| Circadian Rhythm | 5 | 2016 | 85 | 0.570 |
Why?
| Outpatients | 9 | 2022 | 122 | 0.560 |
Why?
| Genetic Variation | 4 | 2014 | 253 | 0.550 |
Why?
| Syndrome | 6 | 2023 | 253 | 0.550 |
Why?
| Resilience, Psychological | 3 | 2021 | 20 | 0.550 |
Why?
| Genetics | 2 | 2018 | 10 | 0.540 |
Why?
| Chaplaincy Service, Hospital | 1 | 2015 | 1 | 0.530 |
Why?
| Interdisciplinary Studies | 1 | 2015 | 4 | 0.530 |
Why?
| Risk Assessment | 7 | 2014 | 1362 | 0.510 |
Why?
| Cross-Sectional Studies | 12 | 2022 | 1696 | 0.510 |
Why?
| Mastodynia | 5 | 2016 | 6 | 0.500 |
Why?
| Melanoma | 1 | 2018 | 313 | 0.490 |
Why?
| Fear | 1 | 2014 | 87 | 0.480 |
Why?
| Internet | 3 | 2016 | 275 | 0.480 |
Why?
| Aging | 5 | 2015 | 784 | 0.470 |
Why?
| Patient Education as Topic | 4 | 2011 | 311 | 0.470 |
Why?
| Survivors | 1 | 2014 | 137 | 0.470 |
Why?
| Chronic Pain | 3 | 2023 | 149 | 0.450 |
Why?
| Research Personnel | 5 | 2019 | 69 | 0.450 |
Why?
| Physician-Patient Relations | 3 | 2016 | 134 | 0.450 |
Why?
| Clinical Competence | 4 | 2011 | 444 | 0.440 |
Why?
| Motivation | 2 | 2021 | 289 | 0.440 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 541 | 0.430 |
Why?
| Interleukin-6 | 5 | 2014 | 315 | 0.420 |
Why?
| Disclosure | 1 | 2012 | 39 | 0.420 |
Why?
| Patient Care Team | 1 | 2014 | 273 | 0.420 |
Why?
| Symptom Assessment | 5 | 2018 | 38 | 0.420 |
Why?
| Pilot Projects | 8 | 2022 | 807 | 0.390 |
Why?
| Prostatic Neoplasms | 5 | 2013 | 421 | 0.380 |
Why?
| Ethics Committees, Research | 3 | 2019 | 18 | 0.380 |
Why?
| Neoplasm Recurrence, Local | 1 | 2014 | 645 | 0.380 |
Why?
| Patient Acceptance of Health Care | 2 | 2016 | 331 | 0.380 |
Why?
| Socioeconomic Factors | 5 | 2017 | 639 | 0.360 |
Why?
| Attitude | 3 | 2018 | 81 | 0.340 |
Why?
| Medical Oncology | 4 | 2021 | 110 | 0.340 |
Why?
| Parents | 1 | 2012 | 346 | 0.340 |
Why?
| Gastrointestinal Neoplasms | 2 | 2021 | 46 | 0.340 |
Why?
| Clinical Protocols | 2 | 2006 | 122 | 0.340 |
Why?
| Attention | 4 | 2014 | 185 | 0.340 |
Why?
| Faculty, Medical | 1 | 2010 | 100 | 0.340 |
Why?
| Prevalence | 10 | 2020 | 1025 | 0.330 |
Why?
| California | 9 | 2020 | 90 | 0.320 |
Why?
| Research | 2 | 2006 | 117 | 0.320 |
Why?
| Sleep | 4 | 2022 | 188 | 0.320 |
Why?
| Smoking Cessation | 1 | 2011 | 311 | 0.320 |
Why?
| Student Health Services | 1 | 2008 | 7 | 0.320 |
Why?
| Multimedia | 3 | 2017 | 6 | 0.310 |
Why?
| Burnout, Professional | 1 | 2008 | 57 | 0.300 |
Why?
| Wakefulness | 3 | 2012 | 59 | 0.300 |
Why?
| Neuropsychological Tests | 3 | 2012 | 363 | 0.300 |
Why?
| Academic Medical Centers | 1 | 2008 | 146 | 0.290 |
Why?
| Aptitude | 1 | 2006 | 4 | 0.290 |
Why?
| Choice Behavior | 1 | 2008 | 95 | 0.290 |
Why?
| Young Adult | 12 | 2020 | 4318 | 0.290 |
Why?
| Age Factors | 11 | 2016 | 1199 | 0.290 |
Why?
| Life Change Events | 2 | 2017 | 41 | 0.280 |
Why?
| Genotype | 8 | 2015 | 600 | 0.270 |
Why?
| Placebos | 1 | 2005 | 90 | 0.270 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2016 | 594 | 0.270 |
Why?
| Tenosynovitis | 1 | 2005 | 6 | 0.260 |
Why?
| Factor Analysis, Statistical | 7 | 2017 | 76 | 0.260 |
Why?
| United States | 16 | 2020 | 5208 | 0.260 |
Why?
| Phenotype | 8 | 2016 | 819 | 0.260 |
Why?
| Students, Medical | 1 | 2008 | 178 | 0.260 |
Why?
| Reimbursement, Incentive | 1 | 2005 | 14 | 0.260 |
Why?
| Tendons | 1 | 2005 | 32 | 0.260 |
Why?
| Health Promotion | 1 | 2008 | 300 | 0.250 |
Why?
| Foot | 1 | 2005 | 50 | 0.250 |
Why?
| Emotions | 3 | 2020 | 170 | 0.240 |
Why?
| Risk Factors | 12 | 2021 | 3937 | 0.240 |
Why?
| Hospice Care | 3 | 2012 | 27 | 0.240 |
Why?
| Psychosocial Deprivation | 1 | 2003 | 3 | 0.240 |
Why?
| Head Injuries, Closed | 1 | 2003 | 9 | 0.230 |
Why?
| Ethics, Clinical | 1 | 2003 | 11 | 0.230 |
Why?
| Random Allocation | 3 | 2017 | 312 | 0.230 |
Why?
| Interviews as Topic | 3 | 2013 | 314 | 0.230 |
Why?
| Pain, Postoperative | 3 | 2014 | 160 | 0.230 |
Why?
| Prospective Studies | 11 | 2021 | 2606 | 0.230 |
Why?
| Cohort Studies | 5 | 2020 | 1546 | 0.230 |
Why?
| Health Status | 5 | 2023 | 368 | 0.230 |
Why?
| Psychometrics | 5 | 2007 | 239 | 0.230 |
Why?
| Patient Care | 1 | 2003 | 65 | 0.230 |
Why?
| Research Design | 6 | 2012 | 375 | 0.220 |
Why?
| Genital Neoplasms, Female | 1 | 2023 | 41 | 0.220 |
Why?
| Follow-Up Studies | 4 | 2018 | 2390 | 0.220 |
Why?
| Genetic Predisposition to Disease | 4 | 2014 | 570 | 0.220 |
Why?
| Analysis of Variance | 6 | 2013 | 634 | 0.210 |
Why?
| Career Choice | 1 | 2003 | 114 | 0.210 |
Why?
| Promoter Regions, Genetic | 3 | 2013 | 520 | 0.210 |
Why?
| Reproducibility of Results | 5 | 2024 | 1301 | 0.200 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2014 | 435 | 0.200 |
Why?
| Data Collection | 4 | 2011 | 320 | 0.200 |
Why?
| Sick Role | 1 | 2001 | 14 | 0.200 |
Why?
| Vulnerable Populations | 2 | 2011 | 44 | 0.200 |
Why?
| Chi-Square Distribution | 5 | 2015 | 318 | 0.200 |
Why?
| Mood Disorders | 1 | 2021 | 63 | 0.190 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2021 | 81 | 0.190 |
Why?
| Pregnancy Trimester, First | 1 | 2020 | 32 | 0.190 |
Why?
| Age Distribution | 4 | 2014 | 199 | 0.190 |
Why?
| Antibodies, Neutralizing | 1 | 2020 | 76 | 0.190 |
Why?
| Physical Endurance | 1 | 2020 | 49 | 0.190 |
Why?
| Antibodies, Viral | 1 | 2020 | 124 | 0.180 |
Why?
| Self Efficacy | 1 | 2001 | 137 | 0.180 |
Why?
| Social Support | 3 | 2015 | 297 | 0.180 |
Why?
| Algorithms | 1 | 2024 | 697 | 0.180 |
Why?
| Immunoglobulin G | 1 | 2020 | 227 | 0.180 |
Why?
| Pregnancy Complications, Infectious | 1 | 2020 | 75 | 0.180 |
Why?
| Feasibility Studies | 4 | 2016 | 398 | 0.180 |
Why?
| Population Surveillance | 1 | 2020 | 183 | 0.180 |
Why?
| Epigenesis, Genetic | 1 | 2023 | 399 | 0.180 |
Why?
| Constipation | 1 | 2019 | 34 | 0.170 |
Why?
| Taste | 1 | 2019 | 37 | 0.170 |
Why?
| Employment | 1 | 2020 | 95 | 0.170 |
Why?
| Family | 4 | 2015 | 191 | 0.170 |
Why?
| Health Services Accessibility | 1 | 2003 | 428 | 0.170 |
Why?
| Breast | 2 | 2021 | 92 | 0.170 |
Why?
| Diarrhea | 1 | 2019 | 90 | 0.170 |
Why?
| Abdominal Pain | 1 | 2019 | 84 | 0.170 |
Why?
| Premenopause | 1 | 2018 | 26 | 0.160 |
Why?
| Specialties, Nursing | 1 | 1998 | 10 | 0.160 |
Why?
| Ruthenium Radioisotopes | 1 | 2018 | 2 | 0.160 |
Why?
| Professional Autonomy | 1 | 1998 | 6 | 0.160 |
Why?
| Proton Therapy | 1 | 2018 | 9 | 0.160 |
Why?
| Career Mobility | 1 | 1998 | 26 | 0.160 |
Why?
| Cholinergic Agents | 1 | 2017 | 4 | 0.160 |
Why?
| Logistic Models | 4 | 2013 | 991 | 0.160 |
Why?
| Education, Nursing, Graduate | 1 | 1998 | 25 | 0.160 |
Why?
| Lung Neoplasms | 2 | 2017 | 643 | 0.160 |
Why?
| Adolescent | 8 | 2020 | 6900 | 0.160 |
Why?
| Brachytherapy | 1 | 2018 | 43 | 0.160 |
Why?
| Antipsychotic Agents | 3 | 2006 | 241 | 0.150 |
Why?
| Social Stigma | 1 | 2018 | 49 | 0.150 |
Why?
| Cognition | 1 | 2020 | 350 | 0.150 |
Why?
| Postmenopause | 1 | 2018 | 102 | 0.150 |
Why?
| Actigraphy | 6 | 2012 | 22 | 0.150 |
Why?
| Spirituality | 1 | 2017 | 30 | 0.150 |
Why?
| Postoperative Period | 2 | 2014 | 189 | 0.150 |
Why?
| STAT Transcription Factors | 1 | 2017 | 7 | 0.150 |
Why?
| Janus Kinases | 1 | 2017 | 8 | 0.150 |
Why?
| Menopause | 1 | 2017 | 61 | 0.150 |
Why?
| Skin Aging | 1 | 1997 | 15 | 0.150 |
Why?
| Antibodies | 1 | 2017 | 178 | 0.150 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.150 |
Why?
| Substance-Related Disorders | 1 | 2003 | 671 | 0.150 |
Why?
| Specialization | 1 | 2017 | 47 | 0.150 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.150 |
Why?
| Education, Medical, Graduate | 2 | 2011 | 226 | 0.150 |
Why?
| Certification | 1 | 2017 | 47 | 0.140 |
Why?
| Hand Strength | 1 | 2016 | 32 | 0.140 |
Why?
| Sex Characteristics | 3 | 2015 | 214 | 0.140 |
Why?
| Multivariate Analysis | 3 | 2013 | 643 | 0.140 |
Why?
| Inflammasomes | 1 | 2017 | 60 | 0.140 |
Why?
| Depression, Postpartum | 1 | 2016 | 42 | 0.140 |
Why?
| Upper Extremity | 1 | 2016 | 50 | 0.140 |
Why?
| Sex Distribution | 2 | 2014 | 159 | 0.140 |
Why?
| Health Services Needs and Demand | 2 | 2014 | 190 | 0.130 |
Why?
| Survival Analysis | 1 | 2017 | 736 | 0.130 |
Why?
| Range of Motion, Articular | 1 | 2016 | 165 | 0.130 |
Why?
| Pain Measurement | 5 | 2015 | 248 | 0.130 |
Why?
| Pandemics | 1 | 2020 | 594 | 0.130 |
Why?
| Potassium Channels | 1 | 2015 | 41 | 0.130 |
Why?
| Estrogens | 1 | 1997 | 244 | 0.130 |
Why?
| Serotonin Agents | 1 | 2014 | 17 | 0.130 |
Why?
| Cluster Analysis | 3 | 2023 | 249 | 0.130 |
Why?
| Catecholamines | 1 | 2014 | 48 | 0.130 |
Why?
| NF-kappa B | 1 | 2017 | 336 | 0.130 |
Why?
| Risk | 2 | 2016 | 343 | 0.130 |
Why?
| Curriculum | 4 | 2011 | 434 | 0.130 |
Why?
| Individuality | 3 | 2021 | 31 | 0.130 |
Why?
| Professional Role | 1 | 2015 | 88 | 0.120 |
Why?
| Receptors, Interferon | 1 | 2014 | 5 | 0.120 |
Why?
| Lymph Node Excision | 3 | 2021 | 140 | 0.120 |
Why?
| Terminal Care | 1 | 2015 | 55 | 0.120 |
Why?
| gamma-Aminobutyric Acid | 1 | 2014 | 76 | 0.120 |
Why?
| Regression Analysis | 5 | 2015 | 445 | 0.120 |
Why?
| Receptors, Interleukin-1 Type I | 1 | 2013 | 2 | 0.120 |
Why?
| Drug Therapy | 2 | 2006 | 50 | 0.120 |
Why?
| Australia | 4 | 2015 | 85 | 0.120 |
Why?
| Models, Statistical | 2 | 2012 | 259 | 0.120 |
Why?
| Educational Status | 3 | 2020 | 261 | 0.120 |
Why?
| NF-kappa B p52 Subunit | 1 | 2013 | 6 | 0.120 |
Why?
| Incidence | 3 | 2013 | 1083 | 0.120 |
Why?
| Home Care Services | 1 | 2015 | 79 | 0.120 |
Why?
| Chemotherapy, Adjuvant | 4 | 2017 | 119 | 0.120 |
Why?
| Linear Models | 4 | 2020 | 308 | 0.110 |
Why?
| Health Services, Indigenous | 1 | 2012 | 5 | 0.110 |
Why?
| Allied Health Occupations | 1 | 2012 | 9 | 0.110 |
Why?
| Guidelines as Topic | 2 | 2013 | 125 | 0.110 |
Why?
| Sex Factors | 4 | 2020 | 766 | 0.110 |
Why?
| Affect | 2 | 2023 | 104 | 0.110 |
Why?
| Activity Cycles | 1 | 2012 | 3 | 0.110 |
Why?
| Genetic Association Studies | 4 | 2014 | 136 | 0.100 |
Why?
| Diagnostic Self Evaluation | 1 | 2011 | 15 | 0.100 |
Why?
| Treatment Failure | 1 | 2011 | 141 | 0.100 |
Why?
| Quality Assurance, Health Care | 1 | 2012 | 164 | 0.100 |
Why?
| Inflammation Mediators | 1 | 2012 | 128 | 0.100 |
Why?
| Psychopharmacology | 1 | 2011 | 5 | 0.100 |
Why?
| Postoperative Complications | 2 | 2016 | 1035 | 0.100 |
Why?
| Societies, Medical | 1 | 2012 | 195 | 0.100 |
Why?
| Preoperative Period | 3 | 2018 | 59 | 0.100 |
Why?
| Suicide | 2 | 2009 | 77 | 0.100 |
Why?
| Family Relations | 1 | 2011 | 25 | 0.100 |
Why?
| Ethics, Medical | 1 | 2011 | 41 | 0.100 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1141 | 0.090 |
Why?
| Psychotropic Drugs | 1 | 2011 | 82 | 0.090 |
Why?
| Time Factors | 6 | 2017 | 3210 | 0.090 |
Why?
| Evidence-Based Practice | 1 | 2011 | 110 | 0.090 |
Why?
| Inpatients | 1 | 2011 | 206 | 0.090 |
Why?
| Knowledge | 2 | 2007 | 31 | 0.090 |
Why?
| England | 2 | 2020 | 61 | 0.090 |
Why?
| Patient Satisfaction | 1 | 2011 | 302 | 0.090 |
Why?
| Government Regulation | 1 | 2009 | 15 | 0.090 |
Why?
| Case-Control Studies | 4 | 2017 | 1229 | 0.090 |
Why?
| New Mexico | 1 | 2009 | 13 | 0.090 |
Why?
| Inflammation | 2 | 2012 | 678 | 0.090 |
Why?
| Prejudice | 1 | 2009 | 43 | 0.080 |
Why?
| Terminally Ill | 1 | 2008 | 15 | 0.080 |
Why?
| Combined Modality Therapy | 1 | 2011 | 693 | 0.080 |
Why?
| Pregnancy | 3 | 2020 | 2639 | 0.080 |
Why?
| Predictive Value of Tests | 3 | 2012 | 1045 | 0.080 |
Why?
| Karnofsky Performance Status | 3 | 2012 | 9 | 0.080 |
Why?
| Mental Health Services | 1 | 2011 | 233 | 0.080 |
Why?
| Demography | 2 | 2022 | 103 | 0.080 |
Why?
| Axilla | 2 | 2020 | 101 | 0.080 |
Why?
| Attitude to Health | 1 | 2010 | 226 | 0.080 |
Why?
| Cross-Cultural Comparison | 1 | 2007 | 29 | 0.080 |
Why?
| Mentors | 1 | 2008 | 55 | 0.080 |
Why?
| Brain Neoplasms | 1 | 2011 | 285 | 0.080 |
Why?
| Smoking | 1 | 2011 | 552 | 0.070 |
Why?
| Mass Screening | 2 | 2007 | 370 | 0.070 |
Why?
| Reference Standards | 1 | 2006 | 63 | 0.070 |
Why?
| Treatment Refusal | 1 | 2006 | 41 | 0.070 |
Why?
| Problem Solving | 1 | 2006 | 46 | 0.070 |
Why?
| Statistics as Topic | 1 | 2006 | 102 | 0.070 |
Why?
| Decision Support Techniques | 1 | 2007 | 73 | 0.070 |
Why?
| Human Experimentation | 1 | 2005 | 11 | 0.070 |
Why?
| Prognosis | 3 | 2018 | 2126 | 0.070 |
Why?
| Hallux Rigidus | 1 | 2005 | 1 | 0.070 |
Why?
| Models, Economic | 1 | 2005 | 19 | 0.070 |
Why?
| Bipolar Disorder | 1 | 2007 | 209 | 0.070 |
Why?
| Delivery of Health Care | 2 | 2024 | 325 | 0.060 |
Why?
| Infant, Newborn | 1 | 2012 | 2923 | 0.060 |
Why?
| Primary Health Care | 1 | 2008 | 398 | 0.060 |
Why?
| Haplotypes | 2 | 2014 | 105 | 0.060 |
Why?
| Scotland | 1 | 2003 | 7 | 0.060 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 922 | 0.060 |
Why?
| Abbreviated Injury Scale | 1 | 2003 | 7 | 0.060 |
Why?
| Pain Management | 1 | 2005 | 155 | 0.060 |
Why?
| Exercise Therapy | 1 | 2005 | 123 | 0.060 |
Why?
| Treatment Outcome | 5 | 2018 | 5612 | 0.060 |
Why?
| Bioethical Issues | 1 | 2003 | 11 | 0.060 |
Why?
| Multiple Trauma | 1 | 2003 | 34 | 0.060 |
Why?
| Patient Care Planning | 1 | 2004 | 79 | 0.060 |
Why?
| Causality | 2 | 2014 | 46 | 0.060 |
Why?
| Nuclear Reactors | 1 | 1982 | 2 | 0.050 |
Why?
| Personal Satisfaction | 1 | 2023 | 90 | 0.050 |
Why?
| Grief | 1 | 2002 | 9 | 0.050 |
Why?
| Accidents | 1 | 1982 | 24 | 0.050 |
Why?
| Qualitative Research | 1 | 2024 | 326 | 0.050 |
Why?
| Neurosurgical Procedures | 1 | 2003 | 121 | 0.050 |
Why?
| Disease Progression | 2 | 2017 | 915 | 0.050 |
Why?
| Antigen Presentation | 1 | 2001 | 28 | 0.050 |
Why?
| Immune Tolerance | 1 | 2001 | 105 | 0.050 |
Why?
| Reference Values | 1 | 2002 | 354 | 0.050 |
Why?
| Alleles | 2 | 2013 | 277 | 0.050 |
Why?
| Polymorphism, Genetic | 2 | 2014 | 193 | 0.050 |
Why?
| Antigens, Neoplasm | 1 | 2001 | 170 | 0.050 |
Why?
| Seroepidemiologic Studies | 1 | 2020 | 50 | 0.050 |
Why?
| Hospital Mortality | 1 | 2003 | 466 | 0.050 |
Why?
| Survival Rate | 1 | 2003 | 954 | 0.050 |
Why?
| Single-Blind Method | 1 | 2020 | 120 | 0.050 |
Why?
| Ossification, Heterotopic | 1 | 2000 | 8 | 0.050 |
Why?
| Databases, Factual | 1 | 2003 | 683 | 0.050 |
Why?
| Patient Compliance | 1 | 2002 | 247 | 0.050 |
Why?
| Motor Activity | 2 | 2012 | 249 | 0.050 |
Why?
| Religion | 1 | 2020 | 68 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 314 | 0.050 |
Why?
| Prenatal Diagnosis | 1 | 2020 | 113 | 0.040 |
Why?
| ROC Curve | 2 | 2012 | 259 | 0.040 |
Why?
| Mastectomy, Segmental | 1 | 2020 | 95 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2005 | 486 | 0.040 |
Why?
| Clozapine | 1 | 1999 | 24 | 0.040 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2020 | 127 | 0.040 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 142 | 0.040 |
Why?
| DNA Methylation | 1 | 2023 | 575 | 0.040 |
Why?
| Job Description | 1 | 1998 | 10 | 0.040 |
Why?
| Training Support | 1 | 1998 | 14 | 0.040 |
Why?
| Morals | 1 | 2018 | 41 | 0.040 |
Why?
| Population Groups | 1 | 2018 | 8 | 0.040 |
Why?
| Professional Competence | 1 | 1998 | 47 | 0.040 |
Why?
| School Admission Criteria | 1 | 1998 | 37 | 0.040 |
Why?
| Drugs, Investigational | 1 | 2017 | 17 | 0.040 |
Why?
| Amyloid | 1 | 2017 | 29 | 0.040 |
Why?
| Hypesthesia | 1 | 2017 | 18 | 0.040 |
Why?
| Nausea | 1 | 2017 | 53 | 0.040 |
Why?
| Back Pain | 1 | 2017 | 44 | 0.040 |
Why?
| Consent Forms | 1 | 2016 | 5 | 0.040 |
Why?
| Mammaplasty | 1 | 2016 | 45 | 0.040 |
Why?
| Periodicity | 1 | 2016 | 29 | 0.040 |
Why?
| Arthroplasty, Replacement, Hip | 1 | 2000 | 249 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 252 | 0.030 |
Why?
| Health Surveys | 1 | 1997 | 261 | 0.030 |
Why?
| Fellowships and Scholarships | 1 | 2017 | 117 | 0.030 |
Why?
| Geriatric Assessment | 1 | 2016 | 126 | 0.030 |
Why?
| Executive Function | 1 | 2016 | 80 | 0.030 |
Why?
| Neoadjuvant Therapy | 1 | 2016 | 125 | 0.030 |
Why?
| Immunotherapy | 1 | 2017 | 264 | 0.030 |
Why?
| Veterans | 1 | 2002 | 619 | 0.030 |
Why?
| Forecasting | 1 | 2015 | 161 | 0.030 |
Why?
| Time | 1 | 2014 | 36 | 0.030 |
Why?
| Signal Transduction | 1 | 2001 | 1752 | 0.030 |
Why?
| Disability Evaluation | 1 | 2014 | 103 | 0.030 |
Why?
| National Institute of Mental Health (U.S.) | 1 | 2013 | 3 | 0.030 |
Why?
| Data Interpretation, Statistical | 1 | 2015 | 177 | 0.030 |
Why?
| Genetic Testing | 1 | 2015 | 135 | 0.030 |
Why?
| Genetic Markers | 1 | 2014 | 117 | 0.030 |
Why?
| Homozygote | 1 | 2013 | 60 | 0.030 |
Why?
| Cancer Care Facilities | 1 | 2013 | 21 | 0.030 |
Why?
| Heterozygote | 1 | 2013 | 96 | 0.030 |
Why?
| Urination | 1 | 2013 | 18 | 0.030 |
Why?
| Sexuality | 1 | 2013 | 13 | 0.030 |
Why?
| Watchful Waiting | 1 | 2013 | 29 | 0.030 |
Why?
| Prostatectomy | 1 | 2013 | 87 | 0.030 |
Why?
| Queensland | 1 | 2012 | 4 | 0.030 |
Why?
| San Francisco | 1 | 2012 | 11 | 0.030 |
Why?
| Canada | 1 | 2013 | 104 | 0.030 |
Why?
| Disorders of Excessive Somnolence | 1 | 2012 | 7 | 0.030 |
Why?
| Ambulatory Care Facilities | 1 | 2013 | 138 | 0.030 |
Why?
| Exercise | 1 | 2017 | 552 | 0.030 |
Why?
| Interleukin-18 Receptor alpha Subunit | 1 | 2012 | 1 | 0.030 |
Why?
| Sleep Stages | 1 | 2012 | 46 | 0.030 |
Why?
| Interleukin-3 | 1 | 2012 | 13 | 0.030 |
Why?
| Preoperative Care | 1 | 2013 | 184 | 0.030 |
Why?
| Women's Health | 1 | 2012 | 107 | 0.030 |
Why?
| Interview, Psychological | 1 | 2011 | 25 | 0.030 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 868 | 0.030 |
Why?
| Models, Theoretical | 1 | 2012 | 184 | 0.030 |
Why?
| Goals | 1 | 2011 | 49 | 0.020 |
Why?
| Rest | 1 | 2011 | 68 | 0.020 |
Why?
| Odds Ratio | 1 | 2013 | 600 | 0.020 |
Why?
| Polysomnography | 1 | 2010 | 71 | 0.020 |
Why?
| Schools, Medical | 1 | 2011 | 82 | 0.020 |
Why?
| Gene Frequency | 1 | 2010 | 120 | 0.020 |
Why?
| Cost of Illness | 1 | 2011 | 132 | 0.020 |
Why?
| Nursing Methodology Research | 1 | 2010 | 45 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 825 | 0.020 |
Why?
| Tourette Syndrome | 1 | 2009 | 10 | 0.020 |
Why?
| Hospitalization | 2 | 2008 | 704 | 0.020 |
Why?
| Clinical Nursing Research | 1 | 2009 | 10 | 0.020 |
Why?
| Obsessive-Compulsive Disorder | 1 | 2009 | 43 | 0.020 |
Why?
| Electroencephalography | 1 | 2010 | 357 | 0.020 |
Why?
| Personality Disorders | 1 | 2008 | 22 | 0.020 |
Why?
| Federal Government | 1 | 2008 | 5 | 0.020 |
Why?
| Virginia | 1 | 2008 | 14 | 0.020 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2008 | 43 | 0.020 |
Why?
| Credentialing | 1 | 2007 | 9 | 0.020 |
Why?
| Bioethics | 1 | 2007 | 14 | 0.020 |
Why?
| Matched-Pair Analysis | 1 | 2007 | 12 | 0.020 |
Why?
| Audiovisual Aids | 1 | 2007 | 15 | 0.020 |
Why?
| Quality of Health Care | 1 | 2008 | 219 | 0.020 |
Why?
| Reading | 1 | 2007 | 84 | 0.020 |
Why?
| Empiricism | 1 | 2005 | 1 | 0.020 |
Why?
| Chronic Disease | 1 | 2008 | 614 | 0.020 |
Why?
| Length of Stay | 1 | 2008 | 683 | 0.020 |
Why?
| Intelligence Tests | 1 | 2004 | 44 | 0.020 |
Why?
| Interdisciplinary Communication | 1 | 2003 | 64 | 0.010 |
Why?
| Advisory Committees | 1 | 2003 | 66 | 0.010 |
Why?
| Crisis Intervention | 1 | 1982 | 10 | 0.010 |
Why?
| Pennsylvania | 1 | 1982 | 35 | 0.010 |
Why?
| Bereavement | 1 | 2002 | 8 | 0.010 |
Why?
| Listeriosis | 1 | 2001 | 7 | 0.010 |
Why?
| Papillomavirus E7 Proteins | 1 | 2001 | 33 | 0.010 |
Why?
| Antigens, Bacterial | 1 | 2001 | 63 | 0.010 |
Why?
| Injections, Intravenous | 1 | 2001 | 148 | 0.010 |
Why?
| Skin Transplantation | 1 | 2001 | 50 | 0.010 |
Why?
| Oncogene Proteins, Viral | 1 | 2001 | 57 | 0.010 |
Why?
| Keratinocytes | 1 | 2001 | 96 | 0.010 |
Why?
| Papillomaviridae | 1 | 2001 | 107 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2001 | 477 | 0.010 |
Why?
| Graft Rejection | 1 | 2001 | 161 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2001 | 658 | 0.010 |
Why?
| Haloperidol | 1 | 1999 | 41 | 0.010 |
Why?
| Gastrointestinal Diseases | 1 | 2000 | 134 | 0.010 |
Why?
| Radiography | 1 | 2000 | 526 | 0.010 |
Why?
| Cross-Over Studies | 1 | 1999 | 250 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 1999 | 401 | 0.010 |
Why?
| Cells, Cultured | 1 | 2001 | 1737 | 0.010 |
Why?
| Double-Blind Method | 1 | 1999 | 743 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2001 | 2001 | 0.010 |
Why?
| Retrospective Studies | 1 | 2008 | 6459 | 0.010 |
Why?
| Mice | 1 | 2001 | 6428 | 0.010 |
Why?
| Animals | 1 | 2001 | 14409 | 0.000 |
Why?
|
|
Dunn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|